Cost-effectiveness of atorvastatin in the treatment of coronary atherosclerosis. An analysis based on the ASCOT trial;Kosteneffektivität von atorvastatin zur prävention der koronaren herzkrankheit. Eine analyse der ASCOT studie

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 25-26, 2004, Pages 1420-1424

  Szucs, T D ^a   Klose, G ^b   Dusing R ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Klinikum Links der Weser   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GERMANY; HEALTH CARE; HUMAN; PROPHYLAXIS; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HEALTH CARE COSTS; HEPTANOIC ACIDS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 3042778717     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826883     Document Type: Article

References (42)

1. Beck JR, Kassirer JP, Pauker SG et al. A convenient approximation of life expectancy - the DEALE. I. Validation of the method. II. Use in medical decision-making. Am J Med 1982; 73: 883-897
2. Berger K, Klose G, Szucs TD. Die Wirtschaftlichkeit von Arzneimitteltherapien am Beispiel von Pravastatin. Med Klin 1997; 92: 363-369
3. Bonita R, Beaglehole R, North JD. Event, incidence and case fatality rates of cerebrovascular disease in Auckland, New Zealand. Am J Epidemiol 1984; 120: 236-243
4. Caro J et al. for the West of Scotland Coronary Prevention Group. Economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-1582
5. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622
6. Drummond MF, Jefferson TO on behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-283
7. Ess SM, Luscher TF, Szucs TD. High dose lisinopril in heart failure: economic considerations. Cardiovasc Drugs Ther 2002; 16: 365-371
8. Haldemann R, Luscher TF, Szucs TD. Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study. Schweiz Rundsch Med Prax 2001; 90: 539-545
9. Johannesson M, Jönsson B, Kjekshus J et al. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336
10. Jönsson B, Johannesson M, Kjekshus J et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001-1007
11. Kolominsky-Rabas PL, Sarti C, Heuschmann PU et al. A prospective community-based study of stroke in Germany - the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke 1998; 29: 2501-2506
12. Laupacis A, Feeny CD et al. How attractive does a new technology have to be to warrant adoption and utilization? Can Med Assoc J 1992; 146: 473-481
13. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003; 21: 651-659
14. Long-Term Intervention with Pravastatin in Ischaemic Disease (UPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357
15. Mark DB, Hlatky MA, Califf RM et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1431
16. Obermann K, von der Schulenburg JM, Mautner GC. Ökonomische Analyse der Sekundärprävention der koronaren Herzkrankheit mit Simvastatin (Zocor-®) in Deutschland. Med Klin 1997; 92: 686-694
17. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high risk patients. Stroke 1994; 25: 1149-1156
18. Pedersen TR, Kjekshus J, Berg K et al. Cholesterol Lowering and the Use of Healthcare Resources: Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796-1802
19. Pharoah PDP, Hollingworth W. Cost-effectiveness of cholesterol-lowering concentration with statins in patients with and without pre-existing coronary heart disease. BMJ 1996; 312: 1443-1448
20. Prosser LA, Stinnett AA et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Int Med 2000; 132: 769-779
21. Rote Liste, Verlag Cantor, Aulendorf, 2003
22. Ruckdäschel St, Berger K, Szucs Th. Koronare Herzkrankheit - ein sozioökonomisches Problem? Münch med Wschr 1996; 138: 404-408
23. Sacks FM, Pfeffer MA, Moye LA et al. for the cholesterol and recurrentevents trial investigators (CARE): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
24. Scandinavian Simvastatin Survival Study Group (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
25. Schulenburg Graf vd JM, Greiner W, Schöffski O et al. Empfehlungen zur gesundheits-ökonomischen Evaluation - Hannoveraner Consensus -. Zeitschr Allgemeinmedizin 1996; 72: 485-490
26. Sever PS, Dahlöf B, Poulter NR et al. Rationale, design, methods and baseline demography of the participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139-1147
27. Sever PS, Dahlöf B et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average Cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA). Lancet 2003; 361: 1149-1158
28. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group (WOS): Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
29. Smith DG, Leslie SJ, Szucs TD et al. Cost of Treating to a Modified European Atherosclerosis Society LDL-C Target. Comparison of Atorvastatin with Fluvastatin, Pravastatin and Simvastatin. Clin Drug Invest 1999; 17: 185-193
30. Smith DG, McBumey CR. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). PharmacoEconomics 2003; 21 (Suppl 1); 13-23
31. Statistisches Bundesamt. Bundesgesundheitssurvey, Wiesbaden, 2002. Erhältlich unter http://www.rki.de/GESUND/DATEN/BGSURVEY/BGSURVEY.HTM (zuletzt aufgerufen 4.112003,
32. Stiftung Deutsche Schlaganfallhilfe. www.schlaganfall-hilfe.de,
33. Szucs TD, Guggenberger G, Berger K, März W, Schäfer JR. Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprä vention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten. Herz 1998; 23: 319-329
34. Szucs T, Berger K, März W, Schäfer JR, Kosten-Effektivität von Pravastatin in der koronaren Sekundärprävention bei Patienten mit Myokardinfarkt oder instabiler Angina Pectoris in Deutschland. Eine Analyse auf der Grundlage der LIPID-Studie. Herz 2000; 25: 487-494
35. Szucs T, Berger K, Schulte-Hillen I, Kleber FX. Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klinik 1995; 91: 112-118
36. Szucs TD, Lüscher TF, Gutzwiller F. Einfluss der medikamentösen Cholesterinsenkung auf den Ressourcenyerbrauch im Gesundheitswesen - Bedeutung der Scandinavian Simvastatin Survival Study (4-S Studie) für die Kostenreduktion unter Schweizer Verhältnissen. Schw Med Wschr 1997; 127: 1819-1823
37. Szucs TD, Schwenkglenks M, Berger K, Karsch K. Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study. Z Kardiol 2003; 92: 236-244
38. Tengs TO, Adams ME, Pliskin JS. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-390
39. Thefeld W. Verbreitung der Herz-Kreislauf-Risikofaktoren Hypercholesterinämie. Bundesgesundheitsbl Gesundheitsforschung Gesundheitsschutz 2000; 43: 415-423
40. Troche CJ, Tacke J et al. Cost effectiveness of primary and secondary prevention in cardiovascular diseases. European Heart J 1998; 19 (Supp C); C59-C65
41. Wilson K, Marriott J, Fuller S, Lacey L, Gillen D. A model to assess the cost-effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. PharmacoEconomics 2003; 21 (Suppl 1); 1-11
42. Windler E. Gesundheitsökonomie der Behandlung von Fettstoffwechselstörungen. Herz 2000; 35: 476-486